Arkolith/Insider Trading/CMMB/Form 4

Darvish Nissim

DirectorChemomab Therapeutics Ltd. (CMMB) · full profile →Form 4 · filed Mar 14, 2022
Net Buying
Open-Market Buys
$5K
Open-Market Sells
$0
Net Open-Market Flow
$5K
Transactions
4
1 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 11, 2022Buy(P)1K$4.28$5K1K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 7, 2022Grant(A)7K—$07K
Apr 19, 2021Grant(A)12K—$012K
Mar 16, 2021Grant(A)10K—$010K

Transaction Codes

P
Open-market purchase
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001178913-22-001072) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML